Business
InMed Files PCT Patent Application for Neuroprotection in Glaucoma
InMed Files PCT Patent Application for Neuroprotection in Glaucoma Canada NewsWire...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Files PCT Patent Application for Neuroprotection in Glaucoma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, May 12, 2020\n\n\n\nVANCOUVER, May 12, 2020 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (\"CBN\"), today announced that it has filed a Patent Cooperation Treaty (\"PCT\") application pertaining to the potential of cannabinoids in the prevention of neuron damage associated with glaucoma.\nThe patent application, entitled \"Compositions and Methods for Use of Cannabinoids for Neuroprotection\" represents an important step in protecting the Company's intellectual property and commercial opportunities.\n\"Glaucoma remains a common and debilitating ocular disease for millions of people worldwide.  It is characterized by hallmark symptoms of increased intraocular pressure with associated progressive, irreversible damage to the retinal ganglion cells (\"RGC\") and the optic nerve,\" remarked Dr. Eric Hsu, InMed's Senior Vice President of Preclinical Research and Development. \"In addition to significant anecdotal evidence of specific cannabinoids decreasing intraocular pressure, our preclinical data suggest certain cannabinoids, and particularly CBN, may offer an additional neuroprotective effect for RGC.\"\nWith INM-088, an eye drop formulation of CBN, the Company is exploring the treatment for glaucoma, either as a prospective stand-alone or an adjunct therapy, and in other ocular diseases where neuroprotection may be of benefit.\nGlaucoma is a neurodegenerative disease in which various triggers, including elevated intraocular pressure, induce a cascade of events which ultimately leads to nerve cell death and an irreversible loss of vision. Currently approved glaucoma therapies are typically intended to decrease intraocular pressure, which may lead to an indirect effect of reducing neuron damage in the eye....